title: Potential strategies to avoid progestogen-induced premenstrual disorders.
abstract: Non-hormonal approaches to premenstrual syndrome (PMS) treatment such as selective serotonin reuptake inhibitors are by no means effective for all women and frequently we must resort to endocrine therapy. During many of the hormonal approaches, PMS-like symptoms can be introduced or re-introduced during the necessary cyclical or continuous progestogen component of the therapy. This is seen with combined oral contraception, progestogen only contraception, progestogen therapy for heavy menstrual bleeding and endometriosis, sequential hormone replacement therapy and any therapeutic strategy for premenstrual syndrome where it is necessary to provide endometrial protection, including estrogen suppression of ovulation or add-back during gonadotrophin releasing hormone suppression. The link to progestogen is very often missed by health professionals. When the pattern of symptoms mimics the cyclicity of PMS, it is termed progestogen-induced premenstrual disorder. The need to use progestogen to protect the endometrium from the proliferative actions of estrogen can pose insurmountable difficulties in managing premenstrual disorders. In the absence of any really useful evidence, nearly all practice in this area depends on clinician experience. We cannot afford to wait for adequate research evidence to be produced - it never will - and so we must rely on empirical findings, clinical experience, theoretical strategies and common sense.
authors.affiliation: Obstetrics & Gynaecology, Keele University, School of Medicine, Newcastle Road, Stoke-On-Trent ST4 6QG, UK.
authors.forename: Lucy J
authors.initials: LJ
authors.lastname: Baker
authors.forename: P M S
authors.initials: PM
authors.lastname: O'Brien
mesh_terms: D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D007044:Hysterectomy; D008597:Menstrual Cycle; D011293:Premenstrual Syndrome / Q000139:chemically induced* / Q000628:therapy*; D011372:Progestins / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D011372:Progestins; D017367:Selective Serotonin Reuptake Inhibitors